Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Cash & Current Investments (2021 - 2024)

Opus Genetics (IRD) has disclosed Cash & Current Investments for 8 consecutive years, with $42.4 million as the latest value for Q3 2023.

  • On a quarterly basis, Cash & Current Investments rose 203.53% to $42.4 million in Q3 2023 year-over-year; TTM through Sep 2023 was $42.4 million, a 203.53% increase, with the full-year FY2022 number at $42.7 million, up 72.44% from a year prior.
  • Cash & Current Investments was $42.4 million for Q3 2023 at Opus Genetics, up from $40.0 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $42.7 million in Q4 2022 to a low of $10.6 million in Q1 2021.
  • A 3-year average of $27.0 million and a median of $24.2 million in 2021 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: tumbled 38.34% in 2022, then surged 203.53% in 2023.
  • Opus Genetics' Cash & Current Investments stood at $24.8 million in 2021, then skyrocketed by 72.44% to $42.7 million in 2022, then fell by 0.75% to $42.4 million in 2023.
  • Per Business Quant, the three most recent readings for IRD's Cash & Current Investments are $42.4 million (Q3 2023), $40.0 million (Q2 2023), and $39.0 million (Q1 2023).